prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Her2, Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE or LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: RT BR CA. POST-OP DIAGMOSIS: SAME. OPERATIVE PROCEDURE: RT SEG MAST. CLINICAL HISTORY: NATERIAL SUBMITTED: RIGHTSEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE. FROZEN SECTION: Right breast mass; portion of breast, 7.0 by 4.0 by 3.5 cm with ellipse of skin, 7.0 by 1.0. cm. Lobulated mass, 4.0 by 2.0 by 2.0 cm. Margins grossly free. Frozen Section and Touch Prep Diagnosis: Infiltrating carcinoma with signet ring features. DIAGNOSIS: RIGHT BREAST, MASTECTONY: INFILTRATING DUCT CARCINOKA, SIGNET RING TYRE, POOR NUCLEAR GRADE, 4.0 CM. - CLOSEST SURGICAL MARGINS ARE SUPERIOR AND DEEP (LESS THAN 1. - SURGICAL MARGINS ARE FREE or TUKOR IN PLANES or SECTION. NOTE: ER/PR immunoperoxidase assay and Her-2/MEU will be performed on block A1. s U P P L T L R E P o T. ER/PR. My signature below is attestation that I have reviewed all slides and agree with the. findings. as. noted. below. IDENTITICATION or ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE A1. NO. DISTINCT ITRANOCLEAR STAINING IS IDENTIFIED FOR EITHER RECEPTOR. THERKFORE, BOTH ARE INTERPRETED AS. NEGATIVE. s P P L E x E T. HER-2/NEU. Ny signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. c-erbB2 (HER-2/NEU) IS CARRIED OUT on BLOCK Al (BREAST CANCER) USING A 1:300 DILUTION OF. DARO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE IMTRACELLULAR DOMAIN or c-erbB2) WITHOUT ANTIGEN. RETRIEVAL. DISTINCT COMPLETE MEMBRANS STAINING IS IDENTIFIED IN 60% or TUNOR CELLS. THEREFORE, c-erb82 (KER-. 2/NEU) IS INTERPRETED AS POSITIVE (SCORE 3+).

expanded version (tokens=923) : 
 Histological classification: Infiltrating duct carcinoma, signet ring type, poor nuclear grade, subtype HER2.

Description of necrosis: No mention of necrosis in the report.

Tumor infiltrating lymphocytes: No mention of tumor infiltrating lymphocytes in the report.

Histological grade: Poor nuclear grade.

Nuclear grade: Poor nuclear grade.

Lymphovascular invasion: No mention of lymphovascular invasion in the report.

Calcification: No mention of calcification in the report.

Receptor status: 
- ER/PR: Both are interpreted as negative.
- HER-2/NEU: c-erbB2 (HER-2/NEU) is interpreted as positive (score 3+).

Ancillary testing results: 
- Immunoperoxidase assay for ER/PR and HER-2/NEU.
- Block A1 was used for both testing.
- 60% of tumor cells showed distinct complete membranous staining for c-erb82 (HER-2/NEU) with a score of 3+.
- No distinct intranuclear staining identified for either receptor for ER/PR. Therefore, both are interpreted as negative.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1076) : 
 This breast pathology report shows an infiltrating duct carcinoma with signet ring features, poor nuclear grade and subtype HER2. No necrosis or lymphovascular invasion was reported. ER/PR receptors were negative while c-erbB2 (HER-2/NEU) was positive with a score of 3+. The tumor cells showed distinct complete membranous staining for c-erbB2 (HER-2/NEU). There was no distinct intranuclear staining identified for either receptor for ER/PR.

